Glycine receptors belong to the pentameric Cys-loop receptor family, a class of ligand-gated ion channels that also includes the receptors for GABA, acetylcholine, and serotonin. In the central nervous system, GlyRs mediate a major share of fast inhibitory synaptic transmission by opening a chloride-conducting pore whenever glycine binds. The α3 subunit exists in short and long splice variants, generated by alternative inclusion of exon 8A of the Glra3 gene within the large intracellular loop between transmembrane domains three and four. Although this loop does not touch the ligand binding site or the ion conduction pathway directly, splice-dependent differences influence how the receptor is regulated and trafficked to the neuronal surface.

On top of alternative splicing, glycine receptor transcripts undergo a rare but potent post-transcriptional modification: cytidine-to-uridine RNA editing. In α2- and α3-GlyRs, this editing swaps a proline for a leucine within the extracellular domain, at positions P185 and P192 respectively. The substitution increases the receptor’s sensitivity to glycine, producing a gain-of-function phenotype. Elevated levels of Glra3-encoded mRNA have been observed in temporal lobe epilepsy, and previous work has suggested that RNA-editing-dependent changes in GlyR function may contribute to pathological shifts in neuronal network homeostasis, with consequences ranging from cognitive deficits to anxiety, depending on which neuronal cell types are affected.

The cesium story adds an unusual twist. While sodium, potassium, and lithium ions do not induce measurable GlyR activation, cesium has been shown to activate at least α2- and α3-containing receptors, and ammonium behaves similarly. Earlier work by the same group demonstrated that the RNA-edited variants respond more strongly to both Cs+ and NH4+ at millimolar concentrations than their unedited counterparts. In 2025, the team characterized a predicted allosteric cesium binding site involving positions D141, E192, and D194 near the editable P185 site in the F-loop region, identifying D194 as essential for activation of α3L receptors at the cell surface and E192 as relevant for desensitization of the current response.

For the new study, the researchers turned to five positions predicted to participate in cesium binding closer to the orthosteric glycine site: the acidic residues D91, D97, E110, and D114, plus the neutral polar tyrosine Y161. Using PCR-based mutagenesis, they replaced each of these residues with either alanine, which carries a neutral hydrophobic side chain, or lysine, which carries a positive charge. The mutated constructs were expressed in HEK293T cells together with EGFP, and receptor function was assessed by whole-cell patch-clamp electrophysiology, with glycine applied at a subsaturating concentration of 100 micromolar followed by successive applications of cesium at 0.5, 5, 50, and 150 millimolar. An HA-epitope tag inserted near the mature N-terminus allowed quantitative surface staining by confocal microscopy, so that losses of function could be distinguished from losses of trafficking.

The electrophysiological data revealed a striking hierarchy of importance. Substitutions at D97, whether alanine or lysine, abolished receptor function in response to both agonists, producing only negligible residual currents and no measurable concentration-response parameters. The same was true for Y161K, where the introduction of a positive charge at this position within the B-loop of the binding site proved catastrophic for glycine-dependent activation. By contrast, mutations at D91, E110, and D114 left detectable currents in place, though with clear quantitative consequences: D91A/K variants reduced peak amplitudes for both glycine and cesium and shifted apparent affinities upward, with EC50 values for glycine rising from 8.6 micromolar in the wild-type receptor to 13.3 and 18.1 micromolar for the alanine and lysine mutants respectively, accompanied by reduced Hill slopes indicating diminished cooperativity of ligand gating.

Perhaps the most intriguing result came from the E110 mutants. Both E110A and E110K primarily impaired glycine-evoked currents while leaving cesium-dependent activation essentially intact, and the normalized data showed cesium-evoked currents that were comparable to or even exceeded the glycine response at high cesium concentrations. The E110A substitution also reduced apparent glycine affinity and cooperativity. Meanwhile, D114A showed reduced responses at low cesium concentrations and reduced apparent affinities for both agonists, while D114K retained near-wild-type behavior. At Y161, the neutral alanine substitution nearly eliminated glycine responses but preserved at least some cesium-dependent responsiveness at concentrations above 5 millimolar, indicating that a positive charge at this position is specifically detrimental to glycine-dependent activation.

The surface staining experiments ruled out the simplest explanation for these losses of function. Although the Y161 mutants showed significantly reduced surface expression, the D97 mutants were clearly detectable at the cell membrane despite being completely non-functional, and Y161A, despite its reduced surface levels, still generated significant cesium-evoked currents. This dissociation between surface presence and functional responsiveness indicates that the mutations act by altering the receptor’s activation machinery rather than by preventing the channel from reaching the membrane. The authors note that changes in receptor surface expression do not appear to be responsible for the observed effects on receptor activation.

Structurally, the mutated positions map onto well-defined elements of the Cys-loop receptor extracellular domain. D91 and D97 sit between β-sheets 3 and 4, just before the A-loop, while E110 and D114 lie between β-sheets 5 and 5′, immediately after the A-loop and before the E-loop. Y161 occupies the B-loop directly within the orthosteric glycine binding site. In the established gating model for this receptor family, agonist binding triggers local electrostatic shifts that break resting-state salt bridges, setting off a conformational wave in which the β-sheets twist around the Cys-loop axis. This motion generates mechanical and electrostatic pulling forces that are transmitted through the linker between transmembrane domains two and three, ultimately opening the central ion pore. The new findings bring loops A and B into the structural framework for GlyR activation, complementing earlier work that implicated the F-loop and β-sheet 9.

The authors draw two main conclusions from the complete dataset. First, because no mutant was identified that responded to glycine while lacking cesium-evoked activity, cesium-mediated activation likely involves the same structural framework required for glycine-induced channel opening rather than representing an independent activation mechanism. They propose that cesium, and by extension other monovalent cations of similar ionic radius such as ammonium, may exert a kind of electrostatic pressure on the receptor protein structure, pushing it toward the open-channel conformation through multiple binding sites distributed across the extracellular ligand-binding domain. Second, the alternative possibility remains that positions or combinations of positions not yet examined could be selectively involved in cesium-dependent activation. The study also acknowledges a limitation: only homomeric α receptors were tested, so the contribution of the GlyR β-subunit, which is known to shape ligand binding and current-voltage relationships in synaptic heteromeric receptors, remains to be explored. Together with the earlier identification of D194 as essential and E192 as a desensitization determinant, this work assembles an increasingly detailed electrostatic map of how a chloride channel central to inhibitory neurotransmission can be switched on by two chemically very different keys.

Subject of Research: Molecular determinants of glycine- and cesium-dependent activation of the RNA-edited glycine receptor α3L

Article Title: Identification of critical sites for glycine- and cesium-dependent activation of the RNA-edited glycine receptor α3L

Article References: Novykova, Y., Fricke, S., & Meier, J. C. (2026). Identification of critical sites for glycine- and cesium-dependent activation of the RNA-edited glycine receptor α3L. Frontiers in Molecular Neuroscience, 19, Article 1918246. https://doi.org/10.3389/fnmol.2026.1918246

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.1918246

Keywords: glycine receptor, cesium, RNA editing, ligand-gated ion channel, patch-clamp, Cys-loop receptors, GlyR α3, receptor activation, inhibitory neurotransmission, HEK293T cells, mutagenesis, molecular neuroscience

The focal point of the investigation was PSD-95, or postsynaptic density protein-95, a scaffold protein that anchors NMDA and AMPA glutamate receptors and organizes the signaling cascades responsible for synaptic plasticity. Because PSD-95 physically links receptor localization with calcium/calmodulin-dependent protein kinase II (CaMKII), a central regulator of activity-dependent plasticity, changes in its expression and clustering translate into changes in how excitatory synapses are built and maintained. Disruption of PSD-95 has been implicated in a striking range of conditions, including DLG4-related synaptopathy, a rare genetic disorder caused by pathogenic variants in the gene encoding PSD-95, as well as autism spectrum disorder, schizophrenia, Alzheimer’s disease, and Fragile X syndrome. This makes PSD-95 a high-value target for any intervention claiming to support synaptic health.

The experimental design was deliberately symmetric and composition-controlled. The team used differentiated human SH-SY5Y neuroblastoma cells, a widely employed neuronal-like model, matured over 14 days with retinoic acid and BrainPhys neuronal medium. After differentiation, cultures were treated for 24 hours with DHA alone (50 micromolar), EPA alone (50 micromolar), or defined DHA:EPA molar mixtures of 2:1, 1:1, and 1:2, with the total fatty acid concentration held constant at 50 micromolar across all conditions. This five-point series spanned the full compositional range from pure DHA to pure EPA, allowing the researchers to isolate the effect of the DHA:EPA ratio rather than simply total omega-3 exposure. Vehicle-treated and untreated controls confirmed that the ethanol carrier, kept at or below 0.04 percent, had no detectable influence.

Quantification combined high-content immunofluorescence imaging with Western blot densitometry. Using an Opera Phenix High Content Screening System and a standardized segmentation pipeline in Columbus software, the team measured PSD-95 fluorescence intensity, PSD-95 puncta density within MAP2-positive neurites, and the pixel-wise overlap of PSD-95 with synaptophysin, a presynaptic marker, to approximate Manders’ colocalization coefficients. Protein abundance was assessed by Western blot with stain-free total-protein normalization, a method chosen over single housekeeping proteins because it accounts for lane-to-lane loading variability. An MTT assay confirmed that none of the treatments reduced cellular metabolic activity, meaning the molecular changes could not be attributed to toxicity.

The results were unambiguous. DHA alone produced the largest increase in PSD-95 protein abundance by immunoblot, the strongest increase in PSD-95 puncta density (adjusted p = 0.0005), and the greatest total colocalization with synaptophysin (adjusted p < 0.0001). The proportion of PSD-95 apposed to synaptophysin-positive regions also rose with DHA (adjusted p = 0.0214), whereas EPA actually reduced this proportion relative to control (adjusted p = 0.0079). Among the mixed formulations, the DHA-dominant 2:1 ratio most closely resembled pure DHA, while the equimolar and EPA-dominant compositions showed progressively attenuated responses. Critically, the PSD-95 puncta increases extended into neuronal processes: puncta density normalized to neurite length was significantly elevated by DHA, 2:1, and 1:1 DHA:EPA, indicating that the effect is not confined to the cell body.

The glutamatergic signaling proteins told a consistent story. DHA produced the strongest increase in NMDA receptor expression (adjusted p < 0.0001), with the 2:1 mixture mirroring that response, the 1:1 mixture showing a smaller rise, and the 1:2 mixture failing to differ from control. AMPA receptor expression followed a similar but less pronounced pattern, with DHA again the strongest inducer (adjusted p = 0.0008). CaMKII levels increased across every treatment, though DHA remained the most potent. EPA alone, however, stood out for the wrong reason: it significantly reduced NMDA receptor levels relative to control (adjusted p = 0.0056), demonstrating that EPA is not biologically inert at the synapse but can actively work against the postsynaptic receptor profile that DHA supports.

Why would two structurally similar fatty acids, differing only in two carbons and one double bond, behave so differently? The answer lies in their divergent fates in the brain. DHA is the most abundant long-chain omega-3 in the central nervous system, comprising 10 to 20 percent of neuronal membrane phospholipids and exceeding 30 percent in some synaptic and retinal membranes. It is preferentially esterified into phosphatidylserine and phosphatidylethanolamine, where its six double bonds promote membrane curvature and acyl chain disorder, shaping the lateral organization of membrane microdomains that host glutamate receptors. EPA, by contrast, normally accounts for less than 0.5 percent of brain fatty acids and is rapidly turned over, consistent with a signaling role rather than a structural one. Enzymes such as long-chain acyl-CoA synthetase 6, lysophosphatidylethanolamine acyltransferase 2, and phosphatidylserine synthase 2 preferentially channel DHA into synaptic phospholipids, providing a plausible mechanistic basis for the differential retention the study observed, though these pathways were not directly measured.

The findings carry immediate implications for how omega-3 research and supplementation should be interpreted. Clinical omega-3 formulations vary enormously in DHA:EPA ratio, and prior clinical literature hints that this matters: EPA-predominant preparations have shown greater efficacy in depression, while DHA-containing formulations dominate cognitive and neurodegenerative studies. The new data suggest that when the goal is postsynaptic scaffold stability and glutamatergic signaling, diluting DHA with EPA may attenuate the benefit. The authors are careful to note a key design limitation: because total fatty acid concentration was fixed, increasing the EPA share necessarily decreased the absolute DHA dose, so the study cannot distinguish a true DHA-EPA interaction from a simple reduction in DHA exposure. Other caveats include the acute 24-hour exposure, the use of an immortalized cell line that cannot capture the cellular diversity of the human cortex, and the absence of electrophysiological measurements, meaning the protein changes should be read as evidence of molecular reorganization rather than proven functional enhancement.

Even with those limitations, the study delivers a clear and potentially consequential message: omega-3 effects on synaptic biology depend on fatty acid identity and relative composition, not merely total omega-3 intake. DHA and EPA are not interchangeable, and the DHA:EPA ratio is a modifiable variable that shapes postsynaptic scaffold organization. The research team suggests that future work in human iPSC-derived neurons, lipidomic profiling of membrane remodeling, pathway-inhibition experiments targeting candidates such as PI3K/Akt and MAPK/ERK, and electrophysiological recordings will be needed to determine whether DHA-dominant formulations can translate their molecular signature into genuine synaptic and network benefits. For conditions marked by disrupted PSD-95 organization, from rare genetic synaptopathies to Alzheimer’s disease, the possibility that a carefully tuned lipid composition could stabilize the postsynaptic apparatus offers a compelling, testable direction for lipid-based therapeutics.

Subject of Research: Effects of DHA and EPA omega-3 fatty acid ratios on PSD-95 scaffold organization and glutamatergic signaling in human neuronal cells

Article Title: DHA-dominant Omega-3 compositions enhance PSD-95 organization and glutamatergic protein expression

Article References: Medina, G., Baird, S. D., Rodriguez-Alcocer, L. A., & MacKenzie, A. E. (2026). DHA-dominant Omega-3 compositions enhance PSD-95 organization and glutamatergic protein expression. Frontiers in Synaptic Neuroscience, 18, Article 1947075. https://doi.org/10.3389/fnsyn.2026.1947075

Image Credits: AI Generated

DOI: 10.3389/fnsyn.2026.1947075

Keywords: DHA, EPA, omega-3 fatty acids, PSD-95, synaptic plasticity, glutamate receptors, NMDA receptor, AMPA receptor, CaMKII, SH-SY5Y neurons, postsynaptic density, synaptophysin